IMRA Stock Overview
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.27|
|52 Week High||US$4.36|
|52 Week Low||US$0.97|
|1 Month Change||87.60%|
|3 Month Change||86.07%|
|1 Year Change||-44.36%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-84.87%|
Recent News & Updates
We're Keeping An Eye On IMARA's (NASDAQ:IMRA) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|IMRA||US Pharmaceuticals||US Market|
Return vs Industry: IMRA underperformed the US Pharmaceuticals industry which returned 4.2% over the past year.
Return vs Market: IMRA underperformed the US Market which returned -22.1% over the past year.
|IMRA Average Weekly Movement||22.0%|
|Pharmaceuticals Industry Average Movement||11.5%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: IMRA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.
Volatility Over Time: IMRA's weekly volatility has increased from 15% to 22% over the past year.
About the Company
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.
IMARA Fundamentals Summary
|IMRA fundamental statistics|
Is IMRA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IMRA income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.06|
|Net Profit Margin||0.00%|
How did IMRA perform over the long term?See historical performance and comparison
Is IMRA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IMRA?
Other financial metrics that can be useful for relative valuation.
|What is IMRA's n/a Ratio?|
Price to Book Ratio vs Peers
How does IMRA's PB Ratio compare to its peers?
|IMRA PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
MSTH Mystic Holdings
LBPH Longboard Pharmaceuticals
SHWZ Medicine Man Technologies
Price-To-Book vs Peers: IMRA is good value based on its Price-To-Book Ratio (1x) compared to the peer average (11.2x).
Price to Earnings Ratio vs Industry
How does IMRA's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: IMRA is good value based on its Price-To-Book Ratio (1x) compared to the US Pharmaceuticals industry average (1.7x)
Price to Book Ratio vs Fair Ratio
What is IMRA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||1x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate IMRA's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of IMRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IMRA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IMRA's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is IMARA forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMRA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMRA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMRA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if IMRA's revenue is forecast to grow faster than the US market.
High Growth Revenue: IMRA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IMRA is forecast to be unprofitable in 3 years.
Discover growth companies
How has IMARA performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMRA is currently unprofitable.
Growing Profit Margin: IMRA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMRA is unprofitable, and losses have increased over the past 5 years at a rate of 39.4% per year.
Accelerating Growth: Unable to compare IMRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).
Return on Equity
High ROE: IMRA has a negative Return on Equity (-88.09%), as it is currently unprofitable.
Discover strong past performing companies
How is IMARA's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IMRA's short term assets ($64.3M) exceed its short term liabilities ($3.3M).
Long Term Liabilities: IMRA has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: IMRA is debt free.
Reducing Debt: IMRA had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMRA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMRA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 38.8% each year
Discover healthy companies
What is IMARA current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|IMARA Dividend Yield vs Market|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Pharmaceuticals)||2.5%|
|Analyst forecast in 3 Years (IMARA)||0%|
Notable Dividend: Unable to evaluate IMRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMRA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IMRA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rahul Ballal (44 yo)
Dr. Rahul D. Ballal, Ph D., is the Chief Executive Officer of Imara Inc. June 13, 2018. Dr. Rahul serves as Director of Agios Pharmaceuticals, Inc. since August 2022.Dr. Ballal is President and Director a...
CEO Compensation Analysis
|Rahul Ballal's Compensation vs IMARA Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$2m||US$518k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$626k||US$437k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$2m||US$422k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$938k||US$242k|
Compensation vs Market: Rahul's total compensation ($USD1.95M) is above average for companies of similar size in the US market ($USD784.47K).
Compensation vs Earnings: Rahul's compensation has increased whilst the company is unprofitable.
Experienced Management: IMRA's management team is considered experienced (3.4 years average tenure).
Experienced Board: IMRA's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|16 Jun 22||BuyUS$92,243||BML Capital Management, LLC||Company||83,199||US$1.11|
|06 Jun 22||BuyUS$38,027||BML Capital Management, LLC||Company||33,430||US$1.16|
|17 May 22||BuyUS$50,413||BML Capital Management, LLC||Company||41,145||US$1.26|
|22 Apr 22||BuyUS$783,840||BML Capital Management, LLC||Company||560,000||US$1.40|
|06 Apr 22||SellUS$751,256||New Enterprise Associates, Inc.||Company||694,551||US$1.10|
|23 Feb 22||BuyUS$219,667||David Mott||Individual||151,472||US$1.56|
|17 Feb 22||BuyUS$54,673||David Mott||Individual||45,926||US$1.20|
|14 Feb 22||BuyUS$39,246||David Mott||Individual||31,826||US$1.29|
|25 Jan 22||SellUS$202,209||New Enterprise Associates, Inc.||Company||134,558||US$1.67|
|20 Jan 22||SellUS$48,726||New Enterprise Associates, Inc.||Company||26,555||US$1.89|
|14 Jan 22||SellUS$41,826||New Enterprise Associates, Inc.||Company||21,550||US$2.02|
|11 Jan 22||SellUS$38,740||New Enterprise Associates, Inc.||Company||18,760||US$2.08|
|06 Jan 22||SellUS$72,189||New Enterprise Associates, Inc.||Company||31,916||US$2.34|
|03 Jan 22||SellUS$266,870||New Enterprise Associates, Inc.||Company||116,476||US$2.34|
|29 Dec 21||SellUS$159,500||New Enterprise Associates, Inc.||Company||67,427||US$2.42|
|23 Dec 21||SellUS$584,615||New Enterprise Associates, Inc.||Company||244,152||US$2.95|
|20 Dec 21||SellUS$103,884||New Enterprise Associates, Inc.||Company||47,000||US$2.21|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
IMARA Inc.'s employee growth, exchange listings and data sources
- Name: IMARA Inc.
- Ticker: IMRA
- Exchange: NasdaqGS
- Founded: 2016
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$59.672m
- Shares outstanding: 26.29m
- Website: https://imaratx.com
Number of Employees
- IMARA Inc.
- 116 Huntington Avenue
- 6th Floor
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IMRA||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Mar 2020|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.